All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Asciminib
Therapeutic Area: Oncology Product Name: ABL001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2021
Details:
Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an investigational treatment specifically targeting the ABL myristoyl pocket (STAMP).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Loncastuximab Tesirine,Ibrutinib
Therapeutic Area: Oncology Product Name: Lonca
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
ADC Therapeutics has initiated an expanded access program (EAP) for loncastuximab tesirine (Lonca, formerly ADCT-402) for patients in the U.S. with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tiragolumab,Atezolizumab
Therapeutic Area: Oncology Product Name: RG6058
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2021
Details:
Tiragolumab is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation (BTD) and marks the 37th BTD for Roche’s portfolio of medicines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
People with muscle-invasive urothelial cancer (MIUC) who had detectable circulating tumour DNA (ctDNA) were more likely to benefit from treatment with adjuvant (after surgery) Tecentriq monotherapy, compared with those without ctDNA.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ribociclib,Tamoxifen Citrate,Letrozole
Therapeutic Area: Oncology Product Name: Kisqali
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Kisqali plus endocrine therapy had a median OS of nearly five years (58.7 months), the longest ever reported for premenopausal women with HR+/HER2- metastatic breast cancer (MBC), after a median of 53.5 months follow-up.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Asciminib
Therapeutic Area: Oncology Product Name: ABL001
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib), in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Galinpepimut-S
Therapeutic Area: Oncology Product Name: SLS-001
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: 3D Medicines
Deal Size: $202.0 million Upfront Cash: $7.5 million
Deal Type: Licensing Agreement December 07, 2020
Details:
3DMed gets rights to develop and market SELLAS’ lead late-stage clinical candidate, galinpepimut-S, as and its next generation heptavalent immunotherapeuatic, GPS+ across all therapeutic and diagnostic uses in the Greater China territory.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
